| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $25.1M | — | +41.6% |
| SG&A Expense | $8.2M | — | +0.5% |
| Operating Income | -$33.3M | — | -28.7% |
| Net Income | -$30.9M | — | -36.6% |
| EPS (Basic) | -$1.39 | — | -28.7% |
| EPS (Diluted) | -$1.39 | — | -28.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $124.2M | +19.6% | +75.4% |
| Short-term Investments | $119.0M | -27.9% | -46.3% |
| Current Assets | $246.7M | -9.2% | -16.8% |
| Total Assets | $263.1M | -8.8% | -16.5% |
| Current Liabilities | $18.9M | +15.0% | +33.9% |
| Total Liabilities | $25.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$26.1M | — | -25.7% |
| Capital Expenditures | $281K | — | -64.0% |
| Investing Cash Flow | $46.2M | — | +202.7% |
| Financing Cash Flow | $195K | — | +4775.0% |
| Free Cash Flow | -$26.4M | — | -22.5% |
| +7.9% |
| Stockholders' Equity | $237.8M | -10.2% | -18.5% |